Omexa Biologics - Phoenix - 1

---

Located in Tindivanam, India, Omexa Biologics’ state-of-the-art manufacturing facility is set to be a cornerstone in biosimilar production. Spanning 200,000 sq ft, this facility will house cutting-edge single-use bioreactor technology designed to produce high-quality biologics at scale. With a phased development plan, starting with a 4,000-liter production capacity, the site is strategically positioned to serve both domestic and global markets.

The Tindivanam site embodies Omexa’s commitment to cost-efficient manufacturing, enabling the delivery of affordable, life-saving therapies, particularly in oncology. Phase 1 of the facility is expected to be operational by 2026, supporting Omexa’s goal to transform biologic production and accessibility.